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Susceptibility to anti-glomerular basement membrane disease is
strongly associated with HLA-DRB1 genes
MARGARET FISHER, CHARLES D. PUSEY, ROBERT W. VAUGHAN, and ANDREW J. REES'
Renal Unit, Department of Medicine, Royal Postgraduate Medical School, and Tissue Typing Department, Guyc Hospital, London, England,
United Kingdom
Susceptibility to anti-glomerular basement membrane disease is
strongly associated with HLA-DRB1 genes. Anti-glomerular basement
membrane (anti-GBM) disease is caused by autoimmunity to a component
of the glomerular basement membrane. The major autoantigen has been
identified as the NC1 domain of the a3 chain of type IV collagen, and
patients are characterized by the presence of specific autoantibodies to
this molecule. In common with other autoimmune disorders, there is a
strong association with HLA genes, with up to 80% of patients inheriting
an HLA-DR2 haplotype. To examine the genetic basis of susceptibility to
anti-GBM disease in more detail, the HLA-DRB and DOB alleles
inherited by 82 patients were analyzed using sequence specific oligonucle-
otides. This identified a hicrachy of association of DRB1 genes with
anti-GBM disease, including susceptibility (DRB1*15, DRBI*04), neutral
(DRB 1*03) and protective (DRBI *07) alleles. Analysis of inherited
haplotypes, particularly DRB1*04 and DRB1*07 carrying haplotypes,
provided further evidence that the primary association was with genes at
the DRBI locus. Comparison of the sequences of the positively and
negatively associated alleles showed that polymorphic residues in the
second peptide binding region of the HLA Class II antigen binding groove
segregated with disease. This work supports the hypothesis that the HLA
associations in anti-GBM disease reflect the ability of certain Class II
molecules to bind and present peptides derived from the autoantigen to T
helper cells.
Anti-glomerular basement membrane (anti-GBM) disease is
caused by autoimmunity to a component of the GBM, and
presents with rapidly progressive crescentic glomerulonephritis
that may be associated with pulmonary haemorrhage. It is invari-.
ably associated with anti-GBM antibodies, which have been
shown to be pathogenic by transfer studies in squirrel monkeys [1]
and by rapid recurrence of disease when renal transplantation is
performed in the presence of circulating anti-GBM antibodies.
These antibodies recognize the 232 amino acid carboxy terminal
(NC1) domain of the cs3 chain of type IV collagen [cx3(IV)NC1],
a structural component of specialized basement membranes [21.
Evidence from antibody inhibition studies suggests that autoanti-
bodies from all patients recognize a similar epitope within the
NCI domain [3, 4]. There is mounting evidence that the
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a3(IV)NCI molecule also contains disease specific T cell
epitopes. Patients' T cells proliferate when incubated with affinity
purified a3(IV)NCI in vitro [5], and the responding T cells use T
cell receptors expressing a restricted range of V families [61.
Genetic susceptibility to anti-GBM disease is known to be
associated with HLA-DR2 specificity, and was originally defined
by the serological typing of 17 British Caucasian patients [7]. The
DR2 specificity, however, is encoded by at least five DRBI*15 and
six DRB1*16 alleles [81. Restriction fragment length polymor-
phism (RFLP) analysis of a second group of 53 British patients
showed that this association was with the DRw15, DQw6 haplo-
type [9] while 21 of 23 American patients studied, using a PCR
based method of determining Class II alleles, inherited the
DRB1*1501, DQB*0602 haplotype [10]. These results are sup-
ported by studies from Australia [11] and France [121.
The HLADRB1*1501 or DQB*0602 alleles are strong candi-
date susceptibility genes. Class II molecules play a central role in
the regulation of immune responses, as their primary function is
to bind and present peptides derived from extracellular proteins
to CD4+ T cells. In the thymus, this shapes the T cell repertoire
by the deletion of strongly self-reactive T cells and the positive
selection of T cells with intermediate affinity for self HLA
molecules. In the periphery, this interaction leads to the activation
of T helper cells, which is required to initiate both cell mediated
and humoral responses. Futhermore, in experimental models of
autoimmunity, therapeutic interventions to interfere with T cell
recognition of MHC Class Il-antigenie peptide complexes can
prevent or even treat established disease [13, 141. The HLA
complex, however, contains more than 200 closely linked genes,
the majority of which are involved in the immune response. The
low level of recombination in this region has made it difficult to
determine which of the Class II loci are primarily associated with
disease susceptibility.
To define the HLA Class II locus responsible for susceptibility
to anti-GBM disease, the HLA-DRB and DQB alleles inherited
by a large group of patients were analyzed using PCR based,
sequence specific oligonucleotide (SSO) typing, and were ranked
according to their strength of association with disease. The
haplotype frequencies in patients and controls were compared to
determine whether the associations were due to genes at the DR
or DQ loci, or to closely linked HLA genes. The sequences of the
disease associated Class II alleles were then compared to ascer-
tain whether the associations could be attributed to particular
polymorphic amino acids that form peptide binding pockets along
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the antigen binding groove. The results show a hierachy of
association of HLA DRB1 alleles, from the strongly positive
DRB1°1501 to the strongly negative DRB1*07, but no such
hierachy for DO alleles. Analysis of the inherited haplotypes
supports a primary DR association. These results may be ex-
plained by differences in the polymorphic residues comprising the
second peptide binding region described by Brown et al [151.
Methods
Patients
The patient group consisted of 82 British Caucasoids with
anti-GBM disease who presented with rapidly progressive glomer-
ulonephritis. The diagnosis was established in all cases at the
RPMS by the detection of anti-GBM antibodies in serum with a
highly specific solid phase immunoassay [16], and by direct
immunofluorescence of all available renal biopsies. The specificity
of the autoantibodies was confirmed by Western blotting of
patients' sera on collagenase digests of human GBM, which
showed binding to 56 kDa and 28 kDa bands known to contain
dimeric and monomeric a3(IV)NC1 [171.
Amplification of DRB and DQB genes
Twenty milliliters of heparinized blood were collected from all
patients at presentation and stored at —20°C. Genomic DNA was
isolated from peripheral blood leukocytes by standard proteinase
K digestion followed by phenol/chloroform extraction and ethanol
precipitation [18]. The second exons of DRB and DQB genes
were each amplified from 1 jsg of genomic DNA using primers
described in the 11th International Histocompatibility Workshop
[19]. Amplifications were performed in 100 d of reaction mixture
containing 2.5U Taq polymerase, 2.0 m'vi MgCl2, 0.2 m each of
dATP, dGTP, dTTP and dCTP (Promega Corporation, Madison,
WI, USA), and 25 pmol of each primer. Amplification was carried
out in a thermocycler (Perkin-Elmer Corp, Norwalk, CT, USA)
for 30 cycles with the following conditions: denaturing for one
minute at 94°C, annealing for one minute at 55°C, and extension
for two minutes at 72°C. The efficiency of amplification was
checked by electrophoresis of 10% of the PCR product in a 2%
agarose gel.
Sequence specific oligonucleotide lyping
Five percent of the PCR product was denatured in 0.4 Msodium
hydroxide and dot blotted onto nylon membranes (Amersham,
Buckinghamshire, UK). The filters were hybridized at 42°C with
allele specific 18 mer hiotinylated oligonucleotides from the 11th
Workshop sequences [British Society of Histocompatihility and
Immunogenetics (BSHI) Class II Oligotyping Kit] that defined 40
l)RB and 14 E)QB alleles [191. Filters were washed in 3 M
tetramethylammonium chloride (Sigma, Dorset, UK), 50 mvi Tris
pH 7.2 and 2 mivi EDTA solution, at 58°C for 30 minutes [201.
Hybridization was detected by incubating the filters with Strepta-
vidin-horseradish peroxidase complex and the color developed
with tetramethylbenzidine (Sigma). Each filter was reprobed up to
five times after the color had been removed by washing in
dimethylformamide at 60°C, and the bound oligonucleotides
stripped by washing in boiling 0.5% SDS. The DRB1*1501 and
1502 alleles differ by only one amino acid, so these were deduced
by hybridization with oligonueleotide probes specific for
DRB5*0101 and 0102 alleles, respectively, as the DRB1 and
DRB5 genes are extremely closely linked [21]. The PCR product
was also hybridized with an oligonucleotide probe specific for
position 24 to 31 of DRBI*1501 [9]. This probe was end labeled
with yATP32 by T4 polynucleotide kinase (Promega) and hybrid-
ization was detected by exposure to Kodak ARX film. Washes of
lower stringency were required to detect hybridization of the
DRBI *07 biotinylated SSO, and these results were checked with
a radiolabeled SSO. Positive and negative controls were included
on all filters.
DRBJ*04 sublyping
Genomic DNA from the 35 DRB1*04positive patients was
amplified using primers specific for the second exon of all
DRBI°04 alleles, as described in the 11th Histocompatibility
Workshop. Using the above method, filters were sequentially
hybridized with nine 18 mer biotinylated oligonucleotides (BHSI
Class II Oligotyping Kit) to identi' the DRB1*0401_*0411
alleles.
Statistical analysis
The patients' results were compared with those of 177 randomly
selected healthy British Caucasoid controls, also from the South
East of England, typed by the same methods [22]. The differences
in allele and haplotype frequencies between the patient and
control samples were assessed by chi-square analysis of two by two
contingency tables. Bonferroni corrections were not applied, as
our previous studies had established the association with
DRB1*15 alleles [9]. The relative risk was calculated by a
standard formula for the odds ratio [23]. Due to the presence of
a very strongly associated allele (DRBI*1501), the relative pre-
dispositional effects (RPE) of the remaining alleles were deter-
mined as described by Payami et al [241, to uncover and rank
secondary associations. In this method, the most strongly associ-
ated alleles are sequentially removed from analysis of the geno-
types, and the expected allele frequencies in the controls normal-
ized. The overall frequency distribution of the remaining alleles at
the DRB or DQB loci was compared with the distribution in
controls, using the chi-square test to detect significant deviation.
The associated alleles were detected sequentially according to the
strength of their association with the disease.
Results
HLA DRB associations in anti-GBM disease
The DRB alleles were identified in 82 patients and the results
are shown in Table 1. The strongest association was with the
DRB1 * 1501 allele, which was inherited by 61 of 82 patients (74%)
compared with 28% ot controls (g 46.9, 1' < 0.0001, RR =
7.4). The DRBI°1502 allele was inherited by three patients (4%)
compared with 1.7% of controls, while one patient inherited a
DRBI°150X allele that is yet to be identified by nucleotide
sequencing. DRBI* 1601 and *1602 are inherited by 1.7% of the
normal population and comprise 5.4% of DR2 alleles. Therefore,
at least four of the 65 I)R2 positive patients would have been
expected to inherit a DRBI *16 allele, whereas none were fund.
These results suggest that both DRBI*1501 and *1502 are
associated with susceptibility to anti-GBM disease, whereas
DRB1*16 alleles are not. The frequency of both DRB1*01,
inherited by 8 out of 82 patients (10% vs. 26% of controls, =
8, P < 0.005, RR = 0.26), and DRBI *07 alleles, inherited by 5 out
Table 2. Relative predispositional effects of DRB1 alleles in anti-GBM disease
Patients Controls
DR 2 removed DR 2 and DR removed
Patients Controls Patients Controls
DRB1* N164 N=354 N=89 N=296 N=53 N=217
alleles N(gf) N(gf) x P obsf expf x P obsf expf x2 P
01 8(0.049) 47 (0.133) 7.5 0.006 0.089 0.159 2.1 0.15 0.15 0.21 0.8 0.4
15 75 (0.45) 58 (0.163) 49 0.0001
0301 18 (0.11) 45 (0.127) 0.18 0.7 0.2 0.15 0.92 0.34 0.34 0.21 3.5 0.06
04 36 (0.22) 79 (0.223) 0 1 0.40 0.266 5.5 0.019
11 3 (0.018) 20 (0.056) 3 0.08 0.033 0.067 0.9 0.4 0.06 0.09 0.31 0.6
12 5 (0.03) 5 (0.014) 0.8 0.4 0.056 0.017 2.8 0.09 0.094 0.023 4.2 0.04
13 6 (0.036) 29 (0.081) 3 0.08 0.06 0.097 0.45 0.5 0.11 0.13 0.03 0.9
14 5(0.03) 10 (0.028) 0.02 0.9 0.056 0.033 0.4 0.5 0.094 0.045 1.1 0.3
0701 5 (0.03) 47(0.133) 11.9 0.0006 0.056 0.159 5.3 0.02 0.094 0.22 3.3 0.07
08 2 (0.012) 8 (0.023) 0.2 0.6 0.022 0.027 0.2 0.9 0.037 0.04 0.2 0.7
09 1(0.006) 5 (0.014) 0.1 0.7 0.011 0.017 0.01 0.9 0.018 0.02 0.1 0.7
10 0 1(0.003) 0.16 0.7 0 0.004 0.4 0.5 0 0.004 0.6 0.4
75.86 <0.0001 18.98 <0.05 14.14 <0.2
Significant differences are underlined (P < 0.05)
Abbreviation gf is genotype frequency.
of 82 patients (5% vs. 25.4% of controls, 16.6, P < 0.0001,
RR = 0.15), were significantly reduced in the patient group,
suggesting that these alleles protect against anti-GBM disease.
The presence of one strongly associated allele will lead to a
decrease in the expected frequencies of all remaining alleles. An
appropriate method to examine whether the reduction in allele
frequencies seen is simply a consequence of the increased fre-
quency of one allele has been developed by Payami et al [241.
After removal of DRB1 *15 alleles, there was still a significant
difference in the frequency distribution of the remaining alleles in
patient and control samples (x2 = 18.9, P < 0.05; Table 2). This
analysis revealed a second positive association with anti-GBM
disease. The DRBI *04 alleles (40% vs. 26%, x2 = 5.5, P = 0.019)
were significantly more common in patients. The 35 DRB1*04
patients were subtyped, but the increased frequency was not due
to the over-representation of a particular allele. The relative
frequencies of I)RBI *0401*o41 1 alleles in our patient group, and
in the subgroup of 9 non-DR2 patients, did not differ from those
reported in normal Caucasian populations [251. With the
DRBI*15 alleles removed from the analysis, the frequency of
DRBI*07 remained significantly reduced (5.6% vs. 15.9%, =
5.3, P = 0.02), demonstrating that this negative association is
independent of the increased frequency of DRBI*15. The reduc-
tion in frequency of DRBI *01 alleles, however, was no longer
significant. After removal of DRB1A 15 and DRB1 *04 alleles there
was no significant difference in the distribution of allele frequen-
cies in the patient and control populations.
Using the relative predispositional effects (RPE) analysis the
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Table 1. Allele frequencies at the DRB1 locus in 82 patients with anti-GBM disease and 177 controls, showing the number positive for each allele
and the phenotype frequency (pf)
Patients
N = 82
N
Controls
N = 177
N pf RR
DR
specificity
DRB1
allele
DR 1
0101
0102
0103
8
5
0
3
0.1
0.06
0.04
46
35
2
9
0.26
0.198
0.011
0.051
0.31
0.26
0.7
8
8
0.04
0.04
0.005
0.008
0.8
0.9
DR 2
1501
1502
150X
1601-02
65
61
3
1
0
0.79
0.74
0.04
0.012
53
50
3
0
3
0.316
0.28
0.017
0.017
8.3
7.4
2.2
53
46.9
0.15
0.31
0.0001
0.0001
0.7
0.6
DR 3
DR 4
DR 5
DR 6
0301
0401-11
1101-04
1201-02
1301-05
1401-05
18
35
3
5
6
5
0.22
0.43
0.04
0.06
0.07
0.06
42
73
20
5
29
10
0.237
0.413
0.113
0.028
0.165
0.056
0.9
1.06
0.3
2.2
0.4
1.1
0.025
0.007
3.15
0.9
3.2
0.02
0.9
0.95
0.07
0.4
0.07
0.88
DR 7
DR 8
DR 9
DR 10
0701
0801-04
0901-02
1001
4
2
1
0
0.05
0.024
0.012
45
8
5
1
0.254
0.046
0.028
0.006
0.15
0.5
0.42
16.7
0.2
0.13
0.16
0.002
0.65
0.72
0.7
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Table 3. Allele frequencies at the DQB locus in 80 patients with anti-
GBM disease and 177 controls, showing the number positive for each
allele and the phenotype frequency (pf)
Patients Controls
N=80 N=177DQB* -________ _____
Allele N pf N pf RR x2 P
02 23 0.29 73 0.41 0.57 3.2 0.08
0301 20 0.25 53 0.30 0.78 0.4 0.5
0302 24 0.30 55 0.31 0.95 0.001 0.97
0303 2 0.025 12 0.07 0.35 1.2 0.3
0401 0 1 0.6 0.2 0.7
0402 1 0.013 6 0.034 0.36 0.3 0.6
0501 4 0.05 44 0.25 0.16 13 0.0003
0502 0 3 0.017 0.3 0.6
0503 3 0.04 9 0.05 0.73 0.02 0.9
0504 0 1 0.6 0.2 0.7
0601 1 0.013 4 0.023 0.55 0.001 0.97
0602 61 0.79 48 0.27 8.6 52.5 0.0001
0603 5 0.06 11 0.06 0.7 0.8
0604 3 0.04 9 0.05 0.74 0.02 0.9
alleles at the DRB1 locus were ranked according to their strength
of association with anti-GBM disease. This identified a clear
hierachy of association, with susceptibility (DRB1*15 >
DRBI*04), neutral (DRB1*03), weakly protective (DRBI*01)
and protective (DRB1*07) alleles.
HLA DQB associations in anti-GBM disease
The DQB alleles were identified in 80 of the patients, as
amplification failed in two cases (Table 3). DQB*0602 was
inherited by 61 of the 80 patients (79%) compared with 27% of
controls (x2 = 52.5, P < 0.0001, RR = 8.6). This was expected, as
DQB*0602 is most commonly found on the DRB1* 1501 haplo-
type. The frequency of the DQB*0501 allele, usually linked with
DRBI *0101, was significantly reduced; it was inherited by 4 out of
80 patients (5%) compared with 25% of controls (g = 13, P =
0.0003, RR = 0.16). In contrast to the analysis of DRB alleles
described above, once the strongly associated DQB*0602 alleles
were removed from analysis, no overall significant difference
between the distribution of allele frequencies was identified,
although the reduction in DQB*0501 remained significant (Table
4). The above DQB associations can all be explained by linkage
disequilibrium with DR alleles.
HLA DRB and DQB haplotypes
Linkage between the DRBI and DQA loci is nearly complete
[261; however, due to recombination events in the past, the same
DRB or DOB alleles can occur on different haplotypes. To look
for evidence of a primary DRB or DOB association with anti-
GBM disease, the frequencies of the DRBI and DQB haplotypes,
based on those commonly found in Northern European Cauca-
soids, were determined in 80 patients (Table 5). The DRBI*1501,
DQB*0602 haplotype, which was strongly associated with anti-
GBM disease, and the negatively associated DRBI*0101,
DQB*0501 haplotype were uninformative, as these alleles are
commonly found only on these haplotypes. Two results, however,
suggested a primary association with genes at the DRB1 locus.
Firstly, the DRB1*04 alleles, which are positively associated with
disease, are inherited with either DQB*0301 or DQB*0302
alleles. There was no bias towards inheritance of either haplotype,
suggesting that the DRB1*04 alleles themselves predispose to
disease. Secondly, DQB*02 is commonly found on both DRBI*07
and DRB1*0301 haplotypes, and while the DRBI*0301, DQB*02
haplotype was present in the patient population at the expected
frequency, the frequency of the DRift *07, DQB*02 haplotype
was reduced (1.9% vs. 10%, = 9.2, P = 0.0024). This localizes
the gene affording protection either to the DRBI*07 allele itself
or to an associated gene telomeric to the DR locus.
DRBJ amino acid motif (RFLDRYF) at position 1325—1331 is
associated with anti-GBM disease
The linear amino acid sequences of the positively associated
alleles, DRB1*1501, DRBI*1502 and DRB1*04, were examined
for conserved polymorphic regions. Only one such region, con-
taining five polymorphic amino acids at positions 1325—1331, was
identified, as previously reported from our laboratory [9]. An
oligonucleotide probe specific for the DRBI* 1501 amino acid
sequence at /325—1331 (RFLDRYF) was hybridized with DNA
amplified with the DRB generic primers, from 82 patients and 55
randomly chosen controls. The RFLDRYF motif was detected in
72 of 85 patients (91%), and in 34 of 55 controls (62%) (x2 16,
P <0.0001). The RFLDRYF motif was found in two patients who
were neither DR2 nor DR4, and was due to DRBI*08 and
DRB1*14 alleles but was not detected in the patient with the
unidentified DRBI*15 allele. The amino acids at positions 1325—
1331 lie across the floor of the antigen binding groove, and the
amino acid motif RFLDRYF at this position was more frequently
associated with anti-GBM disease than any single allele.
Polymorphic amino acids in the second peptide binding pocket
influence susceptibility to anti-GBM disease
Resolution of the three dimensional structure of the
DRBI *0101 molecule identified four peptide binding regions
which contain most of the polymorphic residues [15]. The amino
acids comprising these binding regions in the alleles positively
associated with anti-GBM disease were compared with those
found in the negatively associated alleles (Table 6). The main
difference was found in the second peptide binding region (Fig. 1).
The glutamine (Q) at 1370, and the ion-paired residues at /313 and
/328, are all found in the positively associated DRBI*15 and
DRB1*04 alleles. The DRBI *16 alleles, which were not found in
the patient population, differ from the DRB1*15 alleles at resi-
dues /370 and /371. They, like the DRBI*07 allele, have a
negatively charged aspartic acid (D) instead of glutamine at /370,
and a positively charged arginine (R) rather than a small neutral
alanine (A) at /371. The negatively associated DRB1*tll and
DRBI *07 alleles share a nonconservative change at 1313. These
substitutions would alter both the electrostatic charge and the size
of the second peptide binding region. The DRBS genes are
co-expressed with DRB1 *15 and *16 alleles, although the relative
levels of expression are unknown. A similar analysis of DRB5
alleles shows that amino acids in the second peptide binding
region of all DRBS chains more closely resemble those of the
negatively associated alleles. Structural analysis of the DQB
alleles shows no clear associations with disease susceptibility.
Discussion
Anti-GBM disease is now extremely well characterized, and the
presence of pathogenic autoantibodies, which react specifically
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Table 4. Relative predispositional effects of DQB alleles in anti-GBM disease
DQB* 0602 removed
02 18 22.5 43 24.3
1.25 0
2 2.5 9
2 2.5 1)
1.25 (3
1.25 6
18 0.11 45 0.127
1 0.006
5.1 2 0.012
2 0.012
1 0.006
3.4 I 0.006
0.006
0.2 0.7
0.4 0.5
1.8 0.2
(3.16 0.7
0.017 (1.3 0.6
5 0.014 0.1 0.7
with the NCI domain of a3(IV) collagen, enables the definition of
a homogeneous population for immunogenetic studies. Anti-
GBM disease is known to be strongly associated with the HLA-
DR2 specificity and RFLP analysis of a group of 53 British
Caucasian patients showed that the MHC Class TI haplotype,
DRB1 *15, DQw6 was associated with susceptibility to disease [9].
A recent study of 23 American patients, using newer molecular
based methods of typing, confirmed the association with the
DRB1*1501, DQB*0602 haplotype [101. However, neither study
was sufficiently large to determine whether the association was
x2 P
Patients
N = 89
ohs f
Patients Controls
DQB N=160 N=354
alleles N (gfl N ()tf)
02 23 (0.14) 82 (0.232)
0301 21 (0.13) 57 (0.161)
0302 25 (0.16) 58 (0.164)
0303 2 (0.013) 13 (0.037)
0401 0 1 (0.003)
0402 1 (0.006) 6 (0.017)
0501 4 (0.025) 47 (0.133)
0502 0 3 (0.008)
0503 3 (0.02) 9 (0.025)
0504 0 1 (0.003)
0601 1 (0.006) 4 (0.011)
0602 71 (0.44) 51 (0.144)
0603 5 (0.03) 11 (0.031)
0604 3 (0.02) 11 (0.031)
Controls
N = 303
exp f P
4.7 0.03 0.26 0.27 0.01 0.9
0.6 0.5 0.24 0.19 0.7 0.4
0.01 0.9 0.28 0.19 3.3 (1.7
1.5 0.2 0.02 0.04 0.3 0.6
0.2 0.7 0 0.003 0.4 0.5
0.3 0.6 0.01 0.02 0.01 0.9
13.2 0.0003 0.05 0.16 6.4 0.01
(1.3 0.6 0 0.01 0.06 0.8
0.02 0.9 0.03 0.03 0.03 0.9
0.2 0.7 0 0.003 0.4 0.5
0.003 0.97 0.01 0.01 0.2 0.7
53 0.0001 — —
0.07 0.8 0.06 0.04 0.3 0.6
0.3 0.6 0.03 0.04 0.04 0.8
73.7 <0.001 12.15 <0.2
Significant differences are underlined.
Abbreviation gf is genotype frequency.
Table 5. Frequencies of HLA-DRB1 and DQB haplotypes in 80 patients with anti-GBM disease and 177 controls, showing the numbers and
percent of individuals positive for each haplotype and the haplotype frequency (hi)
Patients Controls Patients Controls
N—SO N=177 N=160 N=354
DQB
0501
0501
0503
0301
0602
02
0601
0602
0502
N N % N hf N hf
1.25
2.5
74
1.25
1.25
2.5
59
2
0
PDRB I
0101
0102
0103
0103
1501
1501
1502
1502
16
0301
04
04
11
12
1301/2
130 1/2
1401/4
1401/4
1402/3
07
07
07
08
08
4 5
0
1
2
35
2
0
1
19.8
1.1
0.6
4
0
1
2
0.025
0.006
0.012
36
2
0
1
0.102
0.006
0.003
8
0.04
0.2
0.5
0.005
0.9
0.7
0.5
48
0
2
1
3
27.1
1.1
0.6
1.7
69
1
1
2
0
0.43
0.006
0.006
0.012
50
0
2
1
3
0.14
0.006
0.003
0.008
50.5
0.2
0.3
0.5
0.3
0.0001
0.7
0.6
0.5
0.6
1.6 0.2
(1.05
0
0.8
I
2.5
0.2
0.1
(1.7
0.1
0.3
0.7
0.6
11 13.8 21 11.9
24 30 54 30.5
3 3.75 19 10.7
4 5 5 2.8
0301
0302
0301
0301
0603
0604
0301
0503
0603
02
0301
0303
02
0402
Ii 0.07
25 0.16
3 0.019
4 0.025
3 3.74 10 5.7 3 0.019
3 3.75 11 6.3 3 0.019
3 3.75 35 19.8
1.25 0
1 1.25 8 4.5
09 0303
21 0.06
57 0.16
19 0.054
5 0.014
10 0.028
11 0.028
0
9 0.026
0
35 0.1
0
8 0.023
0
6
3 0.019
0.006
0.006
1.25 5 2.8
9.2 0.0024
(1.2 0.7
0.3 (1.6
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Table 6. Comparison of the polymorphic residues of the second
pcptide binding region of DRBI alleles
Amino acid positionStrength of - ______—
association [328 [370 /371 /374
+++ D Q A A
+ 0401
0403
0404
0405
0406
0407
0410
Neutral 0301
160 1/2
0101
0102
0103
Conserved amino acids at positions [313, /328 and [370 are present in
alleles positively associated with anti-GBM disease, while non-conserva-
tive changes (highlighted) arc found at positions [313, [370 and [371 in the
negatively associated alleles.
primarily due to the DR or DO alleles, or to genes closely linked
to them on the extended haplotype. Precise definition of the MHC
associations with autoimmune diseases is difficult because of the
tight linkage disequilibrium that occurs across the MHC region,
with some haplotypes extending over 2500 kbp.
The SSO typing of 82 patients with anti-GBM disease con-
firmed the strong positive association with DRBI* 1501. Whereas
less common DRB1*15 alleles were also identified in the patient
group, none of the DRBI*16 alleles, which also contribute to the
DR2 specificity, were detected. DRBI*16 alleles are uncommon
in Northern European Caucasian populations, but it is notable
that no DRBI*16 alleles have been identified in any of the patient
series reported (Table 7). Different associations of the DRB1*15
and DRBI *16 alleles with an autoimmune disease are also seen in
insulin dependent diabetes (IDDM), in which the DRB1*15
alleles are protective while DRB1*16 alleles are associated with
susceptibility to disease [27]. To assess the significance of our
findings, studies of the HLA associations with anti-GBM disease
in populations where DRB*16 comprises a higher percentage of
the DR2 specificity, such as the Greek population, are needed.
In anti-GLIM disease, the presence of one strongly associated
allele makes it difficult to assess the changes in the remaining
alleles, as a reduction in all of their frequencies would he
expected. Removal of the DRB1*15 alleles from further analysis
revealed a positive association with DRBI *04, which was consis-
tent with previous findings [9], a neutral effect of 1)RBI*03, and
persistence of the negative association with DRB1*07. This
hierachy of associations with MHC Class II genes has been
reported in other autoimmune disorders [281. A significant part of
the interaction between a peptidc and the antigen binding groove
of Class II molecules is through conserved hydrogen bonds, which
are independent of the peptide side chains or DR polymorphism
DRB1* /313 /326
1501 R F
1502 — —
1503 — —
07
DRB5*
0101
[291. This may allow a peptide to bind to a number of DR
_____
molecules, though with varying affinity, and could explain the
hierachy of association of the DR alleles seen in anti-GBM
disease. In contrast, no hierachy of association was seen on
analysis of the DQB alleles.
Analysis of the less frequent DRB, DOB haplotypes in the
patient population provides further evidence that the DRB1 locus
is the primary association with anti-GBM disease. The
DRBi 1501 and DQB*0602 alleles are found nearly exclusively
H — — — B. — on the same haplotype in Caucasian populations and so are
H — — R unhelpful in this analysis. DRB1*04 alleles are positively associ-H — — — R E ated with the disease, and the lack of bias towards either of the
H — — B. E two DRB1*04 haplotypes suggests this increase is not due to an
—
associated DQB allele. Of particular significance is the reduction
S Y — — K R of the DRBI*07, DQB*02 haplotype. DQB*02 is also commonly
— — — D R found on the DRB1*0301 haplotype, and this haplotype is present
F L E — R — at the expected frequency in patients. Therefore, the reduced
F L E — R — incidence of DRB1*07 is is most likely due to a protective effectF L E D E of the DR molecule. The mechanism by which the DRB1*07Y — E D B. Q allele protects against anti-GBM disease is not known. It is
postulated that this might be due to the negative selection ofY — H D R — potentially autoreactive T cells in the thymus, as seen in an
experimental model of diabetes [301, or may be due to genes
telomeric to the DR locus on the extended haplotype.
As the main role of DR molecules is to bind and present
antigenic peptides to CD4+ T cells, the association of DR alleles
with anti-GBM disease would best be explained by the presence of
polymorphic residues that enable DRB1*15 alleles to bind pep-
tides derived from the Goodpasture antigen. Resolution of the
crystallographic structure of the DRBI*0101 molecule showed a
long open-ended antigen binding groove, which contained most of
the polymorphic residues grouped together in four distinct re-
gions. The allele specificity of peptide binding is determined by
interactions between the peptide side chains and these pockets of
polymorphic residues [311. We therefore compared the polymor-
phic residues of the positively and negatively associated alleles.
Structural differences that segregate with the disease are found in
the second peptide binding region, which contains the linear
sequence RFLDRYF from (325—1331, found to be present in 91%
of patients. The positively associated DRB1*15 and DRB1*04
alleles contain a positively charged residue at /313, which forms an
ion-binding pair with the negatively charged /328 on the floor of
the binding groove. In the negatively associated DRBI*01 and
DRBI *07 alleles, there is a nonconservative substitution of the
positive residue at /313, altering the electrostatic charge that is
known to be important in determining peptide binding to Class II
molecules. A recent functional study of mutated DRB1*0401
molecules confirmed that changes on the floor of the binding
groove may alter the conformation of bound peptide and so
abolish '1 cell recognition [32].
DRB1*15 and DRBI*04 alleles share a glutamine (Q) at
position /370 on the c helix, while the l)RB1*16 and the protective
DRBI*07 alleles contain charged residues, aspartic acid (D) at
/370 and arginine (R) at 1371, which would alter both the size and
charge of this pocket. Residues at /370 and /371 might also contact
the T cell receptor, and so changes in these residues might not
only alter peptide binding but also directly affect T cell responses.
Thus, changes on the side and the floor of the second peptide
binding pocket of DRBI molecules segregate with disease, sug-
gesting that this is an important anchor position in determining
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Fig. 1. A model of the MHC Class 11 molecule
showing the position of the polymorphic amino
acids /313 and /328 on the floor, and /370 and
/371 on the alpha helix, of the antigen binding
groove.
YearCountry
U.K. 82 1997 0.79* 0.43 0 0.1 005h
U.S.A. (10) 23 1993 0.91* 0.35 0 0.13 0.04
France (12) 12 1992 0.92" 0.58 0 0 0
Australia (11) 36 1991 0.64" 0.58 0 0.06 0.03"
peptide binding in anti-GBM disease. This analysis is supported
by studies by Vogt Ct a! [331, defining the DRB1*1501 binding
motif of myelin basic protein (MBP) peptide 85-105, a putative
autoantigen in multiple sclerosis. When the large phenylalanine
that binds to the second pocket was substituted by alanine,
peptide binding to the DRBI* 1501 molecule was totally inhibited,
indicating that this region is a primary anchor site of DRBI*1501.
Other genes are likely to be important in the etiology of the
anti-GBM disease. Analysis of genetic susceptibility to IDDM by
microsatellite analysis has shown that, while the major association
is with genes in the MHC Class II region, at least four other genes,
including one lying in the MUC Class III region, contribute to
disease susceptibility [34]. In anti-GBM disease, the inheritance of
the HLA-B7, DR2 haplotype was associated with increased
severity of disease [35]. This may he due to an effect of the Class
I genes themselves and reflect a specific CD8-T cell mediated
response. Other candidate genes that might influence susceptibil-
ity to anti-GBM disease are from the MI IC Class Ill region, and
include tumor necrosis factor (TNF), heat shock protein (lisp)
and complement genes, all of which are important in the immune
response. Studies in patients with systemic lupus erythematosus
have shown that the DR2 specificity is associated with both low
TNF production and an increased incidence of lupus ncphritis
[36].
As MHC molecules play a central role in regulating the immune
response, inherited polymorphisms are likely to be important in
determining susceptibility to a number of diseases. The present
study, in a well defined group of patients, using newer molecular
techniques to define the Class Ii alleles, shows that alleles at the
HLA DRB1 locus are important in determining susceptibility to
and protection against anti-GBM disease. Furthermore, suscepti-
bility to disease segregates with polymorphisms defining the
second peptide binding region of the DRB1 molecule, supporting
the proposal that HLA associations in autoimmune diseases are
due to allele specific binding and presentation of peptides to
autoreactive T cells. Because the autoantigen in anti-GBM dis-
ease is known, and the gene encoding it cloned and expressed [37,
38], it should be possible to define this MHC—antigen—T cell
interaction by functional studies [39]. As the first step toward this
goal, we are characterizing naturally processed peptides derived
from the Goodpasture antigen and bound to DR molecules on the
surface of antigen binding cells. This has enabled us to identify
two nested sets of peptides that can be eluted from DRB1*1501
molecules [40]. Definition of pathogenic interactions of MHC
molecules with autoantigenic peptides is important for the devel-
opment of more specific immunotherapy [41], such as the design
of synthetic peptides to block this interaction, to induce tolerance
or to act as T cell receptor antagonists.
Reprint requests to Dr. Margaret Fisher, Waikato Academic Division,
Bryan! Education Centre, Waikato 1-lospilal, Private Bag 3200, Hamilton,
New Zealand.
Table 7. Summary of reported HLA-DRBI associations with anti-GBM
disease
No. of
patients
DRB1 allele frequencies (phenotype)
DRB1*15 *04 *16 *01 *07
"P <0.0001
b P 0.002
P = 0.005
dp = 0.05
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